Nasdaq

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...
Seeking Alpha

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and ...

Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year After 4 initiating doses in the first 6 ...
Nasdaq

Pliant Therapeutics Pauses Enrollment and Dosing in BEACON-IPF Phase 2b Trial Following DSMB Recommendation

The Company is actively monitoring the current patients in the BEACON-IPF trial, indicating a commitment to patient safety and well-being. Pliant Therapeutics is maintaining the integrity of the trial ...
WHNT

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease ...

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new ...
WGHP

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology ...

CAMBRIDGE, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, announces new safety and ...